Efficiency and good tolerability of the fixed combination of atorvastatin 10 mg and ezetimibe 10 mg is demonstrated in the article. This combination was used for treatment of dyslipidemia in patients with high and very high total cardiovascular risk, in which the target total cholesterol (TC) and low-density lipoproteins (LDL) cholesterol levels were not reached at background monotherapy with average and high doses of statins. The combination drug reduced TC by 32%, LDL cholesterol – by 47% after 4-week treatment. Percentage of patients achieving their LDL-cholesterol targets was 40% for very high risk patients and 66% for high risk patients. Ezetimibe and atorvastatin fixed combination was well tolerated, with a safety profile similar to statins alone.